Tumor formation in vivo and the in vitro transformation of cells cultured from primary tissues require multiples oncogenic events. These events result from the creation or introduction of dominant acting oncogenes and the inactivation of tumor suppressors. Susceptibility of a cell to the transforming properties of these genes may be modified by other cellular genes that, while not driving the oncogenic process, are necessary for the transduction of the transforming event. The central hypothesis of this proposal is that the protein product of the gene Kinase Suppressor of Ras (KSR) is a potent modifier of cell transformation by oncogenic Ras. The goal of this proposal is to explain the molecular mechanisms underlying the biological actions of this putative modifier. KSR was identified as a loss-of-function allele that suppresses the phenotype of activated Ras in Drosophila and C. elegans. These data indicated that normal KSR may be a positive regulator of Ras-regulated pathways in lower eukaryotes. Analysis of oncogenic Ras-mediated transformation in primary fibroblasts from KSR about mice indicate that KSR functions similarly in mammals. Additional analyses demonstrate that KSR is a specific effector of the Ras/Raf/MEK/ERK kinase cascade. KSR is phosphorylated, and mutation of a subset of these phosphorylation sites causes the redistribution of KSR from the cytoplasm to the nucleus. These observations have lead to the hypotheses that the phosphorylation of KSR determines its subcellular location and that the localization of KSR affects its ability to regulate the Ras/Raf/MEK/ERK kinase cascade and Ras-mediated cell transformation. These hypotheses will be tested by: 1) identifying the sequences in KSR that regulate its subcellular distribution; 2) determining the role of KSR phosphorylation in regulating the distribution of KSR between the cytoplasm and the nucleus; 3) characterizing the physical interaction of KSR with Raf, MEK and ERK and its biological consequences; and 4) determining how the contribution of KSR to cell transformation is affected by its subcellular distribution and phosphorylation.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
1R01CA090400-01A1
Application #
6430333
Study Section
Biochemistry Study Section (BIO)
Program Officer
Blair, Donald G
Project Start
2002-03-01
Project End
2007-02-28
Budget Start
2002-03-01
Budget End
2003-02-28
Support Year
1
Fiscal Year
2002
Total Cost
$254,401
Indirect Cost
Name
University of Nebraska Medical Center
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
City
Omaha
State
NE
Country
United States
Zip Code
68198
Guo, Lili; Volle, Deanna J; Lewis, Robert E (2014) Identification of a truncated kinase suppressor of Ras 2 mRNA in sperm. FEBS Open Bio 4:420-5
Henry, MaLinda D; Costanzo-Garvey, Diane L; Klutho, Paula J et al. (2014) Obesity-dependent dysregulation of glucose homeostasis in kinase suppressor of ras 2-/- mice. Physiol Rep 2:
Potts, Malia B; Kim, Hyun Seok; Fisher, Kurt W et al. (2013) Using functional signature ontology (FUSION) to identify mechanisms of action for natural products. Sci Signal 6:ra90
Fernandez, Mario R; Henry, MaLinda D; Lewis, Robert E (2012) Kinase suppressor of Ras 2 (KSR2) regulates tumor cell transformation via AMPK. Mol Cell Biol 32:3718-31
Eritja, Nuria; Mirantes, Cristina; Llobet, David et al. (2012) ERýý-mediated repression of pro-inflammatory cytokine expression by glucocorticoids reveals a crucial role for TNFýý and IL1ýý in lumen formation and maintenance. J Cell Sci 125:1929-44
Xiao, Ling; Chen, Yuanhong; Ji, Ming et al. (2011) KIBRA protein phosphorylation is regulated by mitotic kinase aurora and protein phosphatase 1. J Biol Chem 286:36304-15
Fisher, Kurt W; Das, Binita; Kortum, Robert L et al. (2011) Kinase suppressor of ras 1 (KSR1) regulates PGC1? and estrogen-related receptor ? to promote oncogenic Ras-dependent anchorage-independent growth. Mol Cell Biol 31:2453-61
Llobet, David; Eritja, Nuria; Domingo, Monica et al. (2011) KSR1 is overexpressed in endometrial carcinoma and regulates proliferation and TRAIL-induced apoptosis by modulating FLIP levels. Am J Pathol 178:1529-43
Klutho, Paula J; Costanzo-Garvey, Diane L; Lewis, Robert E (2011) Regulation of glucose homeostasis by KSR1 and MARK2. PLoS One 6:e29304
Razidlo, Gina L; Johnson, Heidi J; Stoeger, Scott M et al. (2009) KSR1 is required for cell cycle reinitiation following DNA damage. J Biol Chem 284:6705-15

Showing the most recent 10 out of 15 publications